Cognoa Autism Spectrum Disorder (ASD) Digital Therapeutic Engagement and Usability Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04326231 |
Recruitment Status :
Recruiting
First Posted : March 30, 2020
Last Update Posted : March 31, 2020
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Autism Spectrum Disorder | Device: Usability assessment of Cognoa ASD Therapeutic Device | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Cognoa ASD Digital Therapeutic Engagement and Usability Study |
Actual Study Start Date : | March 17, 2020 |
Estimated Primary Completion Date : | July 31, 2020 |
Estimated Study Completion Date : | July 31, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Cognoa ASD Therapeutic Device
Usability assessment of Cognoa ASD Therapeutic Device
|
Device: Usability assessment of Cognoa ASD Therapeutic Device
Usability assessment of Cognoa ASD Therapeutic Device |
- Usability assessment of Cognoa ASD Therapeutic Device [ Time Frame: 4 weeks ]Device usability metrics are measured by weekly survey (e.g. ease of use for child, frustration level, fatigue).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Years to 8 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Functional English language capability in the home environment.
- Parent, Guardian, or legal authorized representative (LAR) must be able to read, understand and sign the Informed Consent Form (ICF)
- Female or Male, > 3 to < 9 years of age and parent/caregiver
- Diagnosis of Autism Spectrum Disorder, within the last 12 months
- Parent, Guardian, or legal authorized representative (LAR) must have smartphone capabilities for downloading Testflight software; test versions of the Cognoa for Child development app; and test versions of the Cognoa Digital Therapeutic app (iOS 12.0 and up and Apple iPhone 8 and higher)
Exclusion Criteria:
- Participants with any other medical, behavioral, or developmental condition that in the opinion of the investigator may confound study data/assessments.
- Participants with planned extensive travel (more than 1 week) during the course of the 4 week intervention time period.
- Participants with deafness or blindness.
- Participants with known physical impairments affecting their ability to use their hands.
- Participants with active diagnosis of epilepsy and uncontrolled seizures.
- Participants whose age on the date of enrollment is outside the target age range

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04326231
Contact: Kelley Abrams, PhD | 408-207-6659 | kelley.abrams@cognoa.com |
United States, California | |
Cognoa | Recruiting |
Palo Alto, California, United States, 94306 | |
Contact: Kelley Abrams, PhD |
Principal Investigator: | Kelley Abrams, PhD | Cognoa, Inc. |
Responsible Party: | Cognoa, Inc. |
ClinicalTrials.gov Identifier: | NCT04326231 |
Other Study ID Numbers: |
PRO-003 |
First Posted: | March 30, 2020 Key Record Dates |
Last Update Posted: | March 31, 2020 |
Last Verified: | March 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Autism Spectrum Disorder Child Development Disorders, Pervasive Neurodevelopmental Disorders Mental Disorders |